Investments, Funding & Disinvestment

The GPP Guidelines set out standards for key pharmacy services, including the sourcing and storage of medicines, prescription assessment, accurate dispensing, patient counselling, confidentiality and record keeping.

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.

The acquisition adds rare endocrine diseases as a new growth area alongside Vertex’s existing focus on cystic fibrosis, hematology, acute pain and renal disease.

The meeting brings together stakeholders to discuss practical approaches to strengthening Ghana’s health system and advancing national UHC priorities.

The new stockpile builds on the Access and Allocation Mechanism established in 2024 during the mpox Public Health Emergency of International Concern (PHEIC).

The platform has grown to serve about 70,000 members across more than 400 companies and connects users with more than 1,200 pharmacies and healthcare providers in the two countries.

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.

Photonova Spectra uses the company’s Deep Silicon detector technology to produce high-definition images while providing spectral and spatial imaging capabilities.

Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.